麻豆传媒

Neurology >

Multiple Sclerosis

News, opinions and meeting coverage in neurology.

PPAR-Gamma Drug May Work in MS

In phase II study, drug diminished inflammatory lesions & cortical atrophy

McDonald Criteria for MS May Incorporate CSF Testing

Revision committee finds OCB testing may be useful in specific cases

NEPAD: Better Endpoint for Progressive MS Trials?

Tweak to 'no evidence of disease activity' standard stiffens criteria for progression

New Hints that Vitamin D Helps MS Patients

Two randomized trials miss endpoints but still strongly suggest benefit

Is 'No Evidence of Disease Activity' a Misnomer in MS?

Many patients still show signs of active disease despite meeting current NEDA criteria

'This is a Quadfecta!' What We Heard This Week

Quotable quotes from 麻豆传媒's sources

FDA Again Warns on Balloon Angioplasty for Neurologic Disorders

Says transvascular autonomic modulation is off-label and dangerous

Fatigue, Leg Dysfunction Predict Multiple Sclerosis Progression

Both associated with subsequent conversion to secondary progressive MS

European MS Guidance Taking Shape

ECTRIMS teases the first-ever MS drug guideline

Remyelinating Drug Flops in MS

Large placebo response, 'inverted U-shaped' dose-response in phase II trial

Registry Data: Lemtrada More Effective than Competing MS Tx

Better than fingolimod or interferon; comparable to natalizumab

New Ampyra Trial Bolsters MS Efficacy Claims

Walking ability, as reported by patients, significantly improved

Fluoxetine Flops as Progressive MS Therapy

Trial may have been underpowered to detect a benefit

Rituximab Bests MS Drugs in Swedish Registry

Rituximab offered drug survival advantage over fingolimod, natalizumab

HIV Drug Fails in Small MS Trial

Casts doubt on novel theory of MS etiology

Home-Based DVD May Motivate Seniors With MS to Exercise

Patients reported improvements in physical fitness, self-confidence

Studies Try to Estimate MS Drug Prices

Meds are expensive but push other costs down

Lemtrada Offers Long-Term Stability in MS Patients

Mean change in EDSS score was only +0.06

Lymphopenia Risk Factors to Watch With DMF

Age, race, baseline lymphocytes, overweight, & vitamin D levels included

Tysabri No Help in SPMS

Drug didnt reduce disability progression but may benefit upper limb function

Novel Drug Bests Interferon at Halting MS Activity

Nearly half of patients on ocrelizumab achieved no evidence of disease activity (NEDA)

Biogen Reports Another Tecfidera PML Case

Non-fatal case is the second one for the oral MS drug.

Novel MS Drug Offers Good Functional Outcomes

Daclizumab HYP beats interferon for patient-centered outcomes

No Surprises with Tysabri-Tecfidera Switch

Discontinuation rates for both agents were in line with those seen in clinical trials

Ballroom Dance a Boon to MS Patients

A small study finds ballroom dance -- waltz, salsa, foxtrot, and others -- may improve function in MS patients.

Does a Cocktail a Day Keep MS Symptoms at Bay?

Patients consuming more of the hard stuff had lower EDSS scores.

Seizure Drug May Help in MS Eye Disease

Phenytoin shows promise for slowing neurodegeneration in optic neuritis.

An 80-Proof Antidote for MS Disability?

Patients consuming more of the hard stuff had lower EDSS scores.

Increasing Tysabri Dosing Interval May Cut PML Risk

No sacrifice of efficacy seen in retrospective analysis.

Novel Drug for Cramping Shows Promise in Early Trial

Could benefit patients with MS spasticity and cervical dystonia.

Skull Size Tied to Disability Risk in MS

BOSTON -- Multiple sclerosis patients with larger intracranial volumes -- a measure of their lifetime maximal brain size -- scored better on cognition and physical function tests than those with smaller skull sizes.

Multiple Sclerosis Risk Tied to Some OCs

BOSTON -- Women using combined oral contraceptives containing norethindrone or levonorgestrel were substantially more likely to develop multiple sclerosis than those not on "The Pill."

Generic Copaxone for MS Passes Clinical Test

BOSTON -- A copycat version of the multiple sclerosis drug Copaxone, known generically as glatiramer acetate, performed similarly to the original product in a head-to-head trial, paving the way for it to win regulatory approval as a generic drug.

Novel Drug Beats Avonex for MS Efficacy; Safety Still a Worry

BOSTON -- Daclizumab HYP cut relapse rates and disability progression in multiple sclerosis patients more effectively than interferon beta-1a (Avonex) in a phase III trial, but liver toxicity with the IL-2 inhibitor reared its head again.

Dalfampridine: Not Just a Walking Aid

DALLAS -- Extended-release dalfampridine (Ampyra) is approved for boosting walking speed in multiple sclerosis patients, but its benefits extend to other aspects of physical function, according to a small study reported here.

CCSVI Practices Suboptimal but Patients Don't Mind

DALLAS -- Canadian multiple sclerosis patients who left the country to undergo the controversial procedure called chronic cerebrospinal venous insufficiency (CCSVI) often received poor pre- and postoperative care, but most were still relatively satisfied overall, a researcher reported here.

Gastro Effects Dog Oral MS Drug Tecfidera

DALLAS -- Large proportions of patients starting on dimethyl fumarate (Tecfidera) for multiple sclerosis need additional medications to manage the drug's GI and other side effects, and a substantial minority ultimately find the drug intolerable.

MS Bladder Problems Show Up Early and Often

Nearly 80% of multiple sclerosis patients in a large registry reported overactive bladder symptoms, and one-third of a separate cohort of newly diagnosed patients also showed urinary dysfunction, researchers reported here.

Striking a Nerve: MS Cured With an OTC Drug?

A neurology researcher is planning a clinical trial of a widely available drug that he thinks could stave off disability in multiple sclerosis patients. How much should he (or we) say publicly about it?

Repeat Botox OK for Urinary Incontinence in MS Patients

COPENHAGEN -- Long-term treatment with serial onabotulinum toxin A (Botox) of urinary incontinence among multiple sclerosis (MS) patients appeared to be safe and effective, researchers reported here.

鈥�

6